EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

Michele Borghesani, Anna Reni, Eleonora Lauricella, Alice Rossi, Viola Moscarda, Elena Trevisani, Irene Torresan, Taymeyah Al-Toubah, Elisabetta Filoni, Claudio Luchini, Riccardo De Robertis, Luca Landoni und 6 weitere

Journal of the National Comprehensive Cancer Network · 2024-07 · 22 (5)

DOI: 10.6004/jnccn.2024.7005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-07. Verfasst von Michele Borghesani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Engineering for Innovation Medicine, Section of Oncology, University and Hospital Trust of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Grading. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-grade neuroendocrine neoplasms (NENs) comprise both well-differentiated grade 3 neuroendocrine tumors (G3 NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs) nearly always include poorly differentiated NEC as the neuroendocrine component. The efficacy and safety of frontline mFOLFIRINOX chemotherapy has never been investigated in patients with high-grade NENs. Patients and Methods: We conducted a multi-institutional retrospective analysis of patients with advanced high-grade NEN of the gastroenteropancreatic tract or of unknown origin seen between February 2016 and April 2023 who received treatment with frontline mFOLFIRINOX.

Results

A total of 35 patients were included (G3 NETs: n=2; NECs: n=25; MiNENs: n=8; stage III: n=5; stage IV: n=30). The objective response rate was 77% (complete response: 3%; partial response: 74%). Median progression-free survival was 12 months (95% CI, 9.2–16.2 months) and median overall survival was 20.6 months (95% CI, 17.2–30.6 months). No significant differences in efficacy were seen according to primary site, histopathology, and Ki-67 proliferative index. All 5 patients with stage III disease who received mFOLFIRINOX obtained an objective response and underwent radical surgery or definitive radiotherapy with curative intent, with a recurrence rate of 40%. Grade 3 or 4 adverse events were observed in 43% of patients (mainly neutropenia and diarrhea). Females were at significantly increased risk of developing severe toxicities. Conclusions: mFOLFIRINOX shows antitumor activity against high-grade NENs. Well-designed, prospective clinical trials are needed to assess the efficacy of mFOLFIRINOX in both the neoadjuvant and metastatic settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm GradingIrinotecanHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultIntestinal NeoplasmsOxaliplatinStomach NeoplasmsFluorouracilLeucovorinTreatment Outcome

Substanzen

IrinotecanOxaliplatinFluorouracilLeucovorinfolfirinox

Autor:innen und Institutionen

  • Department of Engineering for Innovation Medicine, Section of Oncology, University and Hospital Trust of Verona, Verona, Italy.
  • Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy.
  • Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
  • Department of Diagnostics and Public Health, Section of Radiology, University and Hospital Trust of Verona, Verona, Italy.
  • Department of Surgical Odontostomatological and Maternal-Child Sciences, Section of General and Pancreatic Surgery, University and Hospital Trust of Verona, Verona, Italy.

Zitieren

APA

Borghesani, M., Reni, A., Lauricella, E., Rossi, A., Moscarda, V., Trevisani, E., Torresan, I., Al-Toubah, T., Filoni, E., Luchini, C., De Robertis, R., Landoni, L., Scarpa, A., Porta, C., Milella, M., Strosberg, J., Cives, M., & Cingarlini, S. (2024). Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of the National Comprehensive Cancer Network, 22(5). https://doi.org/10.6004/jnccn.2024.7005

Vancouver

Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, et al. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of the National Comprehensive Cancer Network. 2024;22(5). doi:10.6004/jnccn.2024.7005

BibTeX
@article{Borghesani2024,
  author = {Borghesani, Michele and Reni, Anna and Lauricella, Eleonora and Rossi, Alice and Moscarda, Viola and Trevisani, Elena and Torresan, Irene and Al-Toubah, Taymeyah and Filoni, Elisabetta and Luchini, Claudio and De Robertis, Riccardo and Landoni, Luca and Scarpa, Aldo and Porta, Camillo and Milella, Michele and Strosberg, Jonathan and Cives, Mauro and Cingarlini, Sara},
  title = {Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  volume = {22},
  number = {5},
  doi = {10.6004/jnccn.2024.7005}
}
Kostenlos starten →